Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats.
We studied the differences in pharmacokinetics and pharmacodynamics of the same dose of alendronate administered subcutaneously as intermittent bolus injection or continuous infusion in rats. Two rat models of bone disease were applied. Bone cancer was produced by intratibial inoculation of Walker carcinosarcoma cells, and a model of augmented bone resorption was produced by vitamin D(3) treatment of rats that had undergone thyroidparathyroidectomy. Higher amounts of alendronate were found in bones and in internal organs after bolus drug administration as compared with continuous infusion. Drug effects on plasma calcium levels and on urine calcium excretion were similar in both modes of alendronate administration. Results of the study indicate that the pharmacokinetics (disposition) of alendronate is administration-dependent. The total amount found in bone does not directly represent the amount of alendronate that is pharmacologically active at the site of action in the bone and that affects bone remodeling. The findings suggest that there is no pharmacodynamic advantage for continuous infusion of alendronate. It is concluded that the preferred mode of administration should be selected according to secondary clinical criteria (like incidence of adverse effects and convenience of administration).
Stepensky
David
D
Department of Pharmaceutics, School of Pharmacy, The Hebrew University of Jerusalem, P.O. Box 12065, Jerusalem 91120, Israel.
Golomb
Gershon
G
Hoffman
Amnon
A
D019386:Alendronate / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D000818:Animals; D001859:Bone Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000652:urine; D001862:Bone Resorption / Q000188:drug therapy; D002118:Calcium / Q000097:blood / Q000652:urine; D002279:Carcinoma 256, Walker / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000652:urine; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005260:Female; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000652:urine; D008297:Male; D009368:Neoplasm Transplantation; D016105:Parathyroidectomy; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D013965:Thyroidectomy; D013977:Tibia / Q000473:pathology
D002118:Calcium; D019386:Alendronate